Recommended for newborns, expecting parents, and people planning a pregnancy, this test screens for 71+ metabolic conditions that can be treated in newborns.

Ms Anu Acharya, CEO of Mapmygenome announced this news, adding, "Pregnancy and parenthood are among the most joyful experiences in a person's life. We want to make these experiences healthy and tension-free. Babymap allows parents to make informed choices to ensure their newborns and future children stay healthy."

Dr Radha Rama Devi, MD (Peds) at Rainbow Hospital who was instrumental in setting up the first Newborn Screening for preventable causes of mental retardation in India and published the first data on the prevalence of these disorders in the Indian population, said, " Babymap is an excellent idea and will replace the newborn screening tests currently used".

Babymap test requires blood samples for genetic testing using the technology platform Next Generation Sequencing for over 31,000 pathogenic single nucleotide variants and minor insertions and deletions. Following analysis, a session with Mapmygenome's genetic counsellors allows parents to learn about their carrier status and future course of action.

This test starts at Rs 30,000 for individuals, with attractive pricing options for couples and parents of newborns. Mapmygenome plans to market this test through their healthcare partners.